Literature DB >> 20380333

Managing bevacizumab-related toxicities in patients with colorectal cancer.

M Wasif Saif1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20380333

Source DB:  PubMed          Journal:  J Support Oncol        ISSN: 1544-6794


× No keyword cloud information.
  7 in total

Review 1.  Bevacizumab: a review of its use in advanced cancer.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2014-10       Impact factor: 9.546

Review 2.  Management of locally advanced and metastatic colon cancer in elderly patients.

Authors:  Peter C Kurniali; Borys Hrinczenko; Anas Al-Janadi
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

Review 3.  Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumors.

Authors:  Nandini Dey; Pradip De; Leyland-Jones Brian
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

Review 4.  After counterfeit Avastin®--what have we learned and what can be done?

Authors:  Tim K Mackey; Raphael Cuomo; Camille Guerra; Bryan A Liang
Journal:  Nat Rev Clin Oncol       Date:  2015-03-03       Impact factor: 66.675

5.  Imaging features of bowel toxicities in the setting of molecular targeted therapies in cancer patients.

Authors:  E Thornton; S A Howard; J Jagannathan; K M Krajewski; A B Shinagare; K O'Regan; J M Cleary; N H Ramaiya
Journal:  Br J Radiol       Date:  2012-06-06       Impact factor: 3.039

6.  Perirenal hematoma in a patient treated with bevacizumab for metastatic colon cancer: A case report.

Authors:  Min Sung Lee; Il Sang Shin; DO Hyung Kwun; Se Hyung Kim; Hyun Jung Kim; Chan Kyu Kim; Seong Kyu Park; Dae Sik Hong; Jina Yun
Journal:  Oncol Lett       Date:  2016-03-11       Impact factor: 2.967

7.  Safety profiles of current antiangiogenic therapies for metastatic colorectal cancer.

Authors:  Jyotsna Fuloria
Journal:  Onco Targets Ther       Date:  2012-08-17       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.